Halozyme Therapeutics, Inc. cash flow to debt ratio of 30.41% indicates that the company generates enough cash to cover its debts. This level indicates strong financial health.

Halozyme Therapeutics, Inc.'s free cash flow has increased 37.62% from $468.37M last year to $644.59M, signaling increasing performance

Halozyme Therapeutics, Inc.'s debt to equity ratio is 14.95, which means that the company's assets are unhealthy financed, signaling financial risk.

Halozyme Therapeutics, Inc.'s debt has increased relative to shareholder equity from 4.14 last year to 14.95 today, signaling weakened financials

Halozyme Therapeutics, Inc. has a net debt to EBITDA ratio of 3.49x, which exceeds the 3.00x threshold, indicating high leverage and potential financial risk

Halozyme Therapeutics, Inc.'s interest coverage ratio of 46.52 indicates that earnings with good margin can cover interest payments on company debt

Halozyme Therapeutics, Inc.'s profit margin has decreased (43.16%) in the last year from 43.74% to 24.86%, signaling decreasing performance

Halozyme Therapeutics, Inc.'s short-term assets of $825.21M exceed its short-term liabilities of $177.09M

Halozyme Therapeutics, Inc.'s return on assets of 16.05% is higher than the 5.00% threshold, indicating efficient asset utilization

Halozyme Therapeutics, Inc.'s return on equity of 180.63%, is higher than 15.00%, indicating good performance

Halozyme Therapeutics, Inc.'s operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

Halozyme Therapeutics, Inc. had positive net income in 5 out of 5 years, indicating stable and consistent earnings

Halozyme Therapeutics, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

Halozyme Therapeutics, Inc. has a free cash flow yield of 5.30%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Halozyme Therapeutics, Inc.'s yearly earnings has decreased 28.64% since last year from $444.09M to $316.89M, signaling decreasing performance

Halozyme Therapeutics, Inc.'s yearly revenue has increased 37.55% since last year from $1.02B to $1.40B, signaling increasing performance

ROIC 27.42% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

Halozyme Therapeutics, Inc.'s 3-year revenue CAGR of 28.38% is positive, indicating growing revenue over the past 3 years

Halozyme Therapeutics, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Halozyme Therapeutics, Inc. had positive ROE in 5 out of 5 years, indicating consistent and reliable returns on equity

Halozyme Therapeutics, Inc. is overvalued relative to its fair value price of 97.71 based on Discounted Cash Flow model

Halozyme Therapeutics, Inc. has an earnings yield of 3.44%, which is below the 4.00% threshold, indicating the stock may be expensive relative to its earnings

Halozyme Therapeutics, Inc. is overvalued relative to its fair value price of 54.57 based on EBITDA multiple model

Halozyme Therapeutics, Inc. has an EV/EBITDA ratio of 24.73x, which exceeds the 20.00x threshold, indicating the stock may be overvalued relative to its operating earnings

Halozyme Therapeutics, Inc. is undervalued relative to its fair value price of 122.44 based on Earnings Fair Value model

Halozyme Therapeutics, Inc. has a PEG-ratio over 1 which is considered overvalued

Halozyme Therapeutics, Inc. has a price-to-book ratio of 83.84x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Halozyme Therapeutics, Inc. has a price-to-sales ratio of 7.23x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue